Abstract:Cancer is caused by accumulated genomic and epigenetic abnormalities during the development of an individual, particularly during the neonatal period, when developmental plasticity is actively occurring. Myeloid-specific deletion of pten in embryos or after 3 weeks of age causes acute monocytic or myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) following a transient myeloproliferative neoplasm (MPN) in adult mice, which can mimic the human diseases to varying degrees. However, it is not clear how the timing of genomic and epigenetic abnormalities contributes to the disease phenotype in a mouse that is of an age comparable to human children. We hypothesized that during the development/aging process, the timing of when the genomic abnormality or “hit” occurs, such as loss of Pten or Nf1, is a critical determinant of the disease phenotype. We tested this by investigating the effect of somatic deletion of Pten at an age of 8 days, one of the most vulnerable stages for malignancy development in mice with or without a germline mutant Nf1. Through crossbreeding, we generated mice with Ptenfl/flNf1Fcr/+Mx1-Cre+ on a C57BL6/129 genetic background, and conditionally deleted Pten in a myeloid-specific manner by intraperitoneal injection of Poly(I:C). Mice with a pten deletion and mutant Nf1 (ptenkoNf1mut, hereafter referred as double mutant) showed signs of sickness at the end of the 2nd week of life, and all died by age 3-5 weeks (equivalent to 1-3 years old in humans). The natural survival in double mutant mice (n=10) was significantly shorter than those with wild type pten and Nf1 (ptenwt; Nf1wt, hereafter referred as WT, n=6, median 0.9 vs >14 months, p<0.001). At autopsy, the double mutant mice had obvious hepatosplenomegaly compared to the WT littermates, but no lymphadenopathy nor thymus enlargement was detected. We then analyzed 15 littermate pairs with/without mutations at age 3-4 weeks. The spleen and liver sizes in the double mutants were significantly increased compared to that in WT (median weights: spleen-198 vs 69mg, p< 0.001; liver-836 vs 532mg, p=0.013). Peripheral blood (PB) analysis showed no difference in WBC in both groups, but significant decreases in double mutant mice in RBC and Hgb (median RBC-5.6 vs 7.6x106/ul, p=0.010; Hgb-10.1 vs 12.6g/ul, p=0.022), but with a normal MCV. HE and IHC stained tissue sections of formalin-fixed organs with antibodies to B220, CD3e, or F4/80 found increased cellularity in bone marrow (BM), and severe infiltration of mature myeloid cells in double mutant spleens, livers, and lungs. Flow cytometric analysis showed that double mutant mice had significantly increased cells marking for monocyte/macrophages(Mac-1+Gr-1int, or Mac-1+CD115+) and granulocytes (Mac-1+ Gr-1+)[p≤0.001] in BM and PB; both T-cells (CD3e+) and B-cells (CD19) were significantly reduced in PB and spleen (p<0.01); platelets (CD41+Ter119-) were reduced in PB. An erythroid differentiation block [indicative of myelodysplasia (MDS) or leukemia] was found in double mutant mice (significant increases in Ter119+CD71high cells). Pten deleted mice without mutant Nf1had a similar phenotype, but survived longer than double mutant mice (median 1.2 vs 0.9 months, p<0.001). Colony formation assays showed no cytokine hypersensitivity in BM or spleen cells in double mutants in response to GM-CSF or IL-3. Based on the Bethesda proposals for classification of non-lymphoid hematopoietic neoplasms in mice, we believe that we have developed a mouse model of myeloproliferative disease with features of a pediatric unclassifiable mixed MDS/MPN. It also mimics to some degree human Juvenile Myelomonocytic Leukemia (JMML), in terms of age of onset and organ infiltration with myelomonocytic cells, but fails to mimic JMML with respect to GM-CSF hypersensitivity.

Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome

Altered cell differentiation and proliferation in mice lacking p57 KIP2 indicates a role in Beckwith–Wiedemann syndrome

Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development

P57(Kip2) Expression is Related to Carcinogenesis and Tumor Progression in Laryngeal Tissues

Oppositely Imprinted Genes P57(Kip2) And Igf2 Interact In A Mouse Model For Beckwith-Wiedemann Syndrome

Functional Versatility of the CDK Inhibitor p57Kip2

Conditional Mutation of Pkd2 Causes Cystogenesis and Upregulates Beta-Catenin.

Correction: Deficiency of FLCN in Mouse Kidney Led to Development of Polycystic Kidneys and Renal Neoplasia

Down-regulation of P57kip2 Induces Prostate Cancer in the Mouse

P57(Kip2), A Structurally Distinct Member of the P21(Cip1) Cdk Inhibitor Family, is A Candidate Tumor-Suppressor Gene

CDK Inhibitor P57 (kip2) is Negatively Regulated by COP9 Signalosome Subunit 6.

Mice With A Targeted Mutation Of Patched2 Are Viable But Develop Alopecia And Epidermal Hyperplasia

Mitotic CDK1 and 4E-BP1 I: Loss of 4E-BP1 serine 82 phosphorylation promotes proliferative polycystic disease and lymphoma in aged or sublethally irradiated mice

Blocked transcription through KvDMR1 results in absence of methylation and gene silencing resembling Beckwith-Wiedemann syndrome

p57Kip2 is an unrecognized DNA damage response effector molecule that functions in tumor suppression and chemoresistance

Dysfunction in IGF2R Pathway and Associated Perturbations in Autophagy and WNT Processes in Beckwith–Wiedemann Syndrome Cell Lines

Timing of the Loss of Pten is Critical in Determining the Disease Phenotype in Mice- A Mouse Model for Pediatric Mixed Mds/Mpn

Podocyte expression of the CDK-inhibitor p57 during development and disease.

Cleidocranial dysplasia with decreased bone density and biochemical findings of hypophosphatasia

Loss of KMT2C reprograms the epigenomic landscape in hPSCs resulting in NODAL overexpression and a failure of hemogenic endothelium specification

Loss of Bbs8 leads to cystic kidney disease in mice and affects tubulin acetylation through HDAC2